Meeder Asset Management’s Cue Biopharma CUE Stock Holding History

Meeder Asset Management’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-358	Closed	-$263K	–	2202
2020 Q2	$263K	Buy	358 +199	+125%	+$144K	0.02%	530
2020 Q1	$67K	Buy	159 +158	+15,800%	+$76.6K	0.01%	824
2019 Q4	$0	Sell	1 -19	-95%	-$5.97K	﹤0.01%	2280
2019 Q3	$5K	Buy	20 +3	+18%	+$721	﹤0.01%	1751
2019 Q2	$5K	Hold	17	–	–	﹤0.01%	1656
2019 Q1	$4K	Sell	17 -13	-43%	-$2.47K	﹤0.01%	1431
2018 Q4	$4K	Sell	30 -31	-51%	-$5.63K	﹤0.01%	1457
2018 Q3	$16K	Buy	+61	New	+$17.6K	﹤0.01%	1076

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Meeder Asset Management's CUE Position: Q3 2020 in Review

Meeder Asset Management sold out of Cue Biopharma (CUE) in Q3 2020, closing a stake of 358 shares — an estimated $263K sold.

Meeder Asset Management first reported a position in CUE in Q3 2018 and held it in 8 quarters. The position peaked at $263K in Q2 2020. 92 funds tracked by Wall St. Rank hold CUE as of Q3 2020.

Meeder Asset Management reported no remaining Cue Biopharma position as of Q3 2020 after selling out during the quarter.
Meeder Asset Management sold 358 Cue Biopharma shares in Q3 2020, an estimated $263K.
Meeder Asset Management first reported a position in Cue Biopharma in Q3 2018 and held it in 8 quarters.
Meeder Asset Management's Cue Biopharma position peaked at $263K in Q2 2020.
92 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.